Cresilon, a Brooklyn-based startup founded in 2010 by Joe Landolina, a first-year student at New York University, has made significant advances in the field of hemostatic products. Since its inception, the company has raised around $130 million in venture capital and expanded its team to over 80 employees. Recently, Cresilon achieved a major milestone by receiving its second FDA clearance for human use of its innovative product, Traumagel.
Joe Landolina’s journey began when he was just 17 years old. He discovered a unique application for polymers extracted from algae cell walls, finding that these could instantly bond with living tissue. Inspired by this discovery, Landolina aimed to address a critical need in medical care: rapid hemorrhage control. He envisioned a gel that could be introduced into a bleeding wound to quickly create a temporary, yet effective, seal.
Initially, Cresilon’s products were only utilized in veterinary medicine. However, in June of the previous year, the company’s trajectory shifted when their hemostatic gel received FDA clearance for use in humans. This gel was designed for local management of bleeding, such as that from minor cuts and abrasions.
The recent FDA approval for Traumagel marks a significant advancement. This product is engineered to instantly stop bleeding from moderate to severe wounds, such as gunshot injuries, stab wounds, and severe lacerations. Traumagel works by forming an immediate mechanical barrier over the wound, which not only stops the bleeding but also supports the body’s natural clotting process. The gel then allows the natural clot to form independently, enabling the gel to be removed later without disturbing the clot.
This innovative approach is poised to transform how first responders and medical professionals manage traumatic bleeding. Unlike traditional methods that involve packing wounds with gauze, powders, or sponges—a process that can be both painful and cumbersome—Traumagel offers a fast, reliable, and minimally invasive alternative. The simplicity and effectiveness of Traumagel make it an essential tool in trauma care, particularly in environments where rapid response is crucial, such as in trauma hospitals, military operations, and emergency medical services.
Cresilon’s mission extends beyond just providing a new medical product; it aims to revolutionize emergency and trauma care. With a vision of creating a world where the risk of bleeding out is significantly reduced, Cresilon is dedicated to enhancing the speed and reliability of bleeding control in both human and veterinary medicine.
Landolina’s passion is evident as he discusses the advantages of Cresilon’s gel over traditional bleeding control methods. By reducing the physical and time-consuming process of wound packing, Cresilon’s products not only alleviate the pain associated with such methods but also potentially reduce the risk of further injury or infection.
As Cresilon continues to grow and evolve, its impact on the medical field appears promising. With two FDA clearances under its belt and a clear vision for the future, Cresilon is well on its way to becoming a key player in the medical technology industry, possibly changing how bleeding injuries are treated across various settings. This is especially crucial in a time when quick and efficient trauma care can mean the difference between life and death.
#FDA #Clears #Gel #Stop #Bleeding #Seconds
